BACKGROUND: Gestational opioid use/misuse is escalating in the United States; however, little is understood about the fetal effects of medications used to treat maternal opioid use disorders. OBJECTIVE: The purpose of this study was to determine the effect of maternal buprenorphine administration on longitudinal fetal neurobehavioral development. STUDY DESIGN: Forty-nine buprenorphine-maintained women who attended a substance use disorder treatment facility with generally uncomplicated pregnancies underwent fetal monitoring for 60 minutes at times of trough and peak maternal buprenorphine levels. Data were collected at 24, 28, 32, and 36 weeks gestation. Fetal neurobehavioral indicators (ie, heart rate, motor activity, and their integration [fetal movementefetal heart rate coupling]) were collected via an actocardiograph, digitized and quantified. Longitudinal data analysis relied on hierarchic linear modeling. RESULTS: Fetal heart rate, heart rate variability, and heart rate accelerations were significantly reduced at peak vs trough maternal buprenorphine levels. Effects were significant either by or after 28 weeks gestation and tended to intensify with advancing gestation. Fetal motor
activity and fetal movementefetal heart rate coupling were depressed from peak to trough at 36 weeks gestation. Polysubstance exposure did not significantly affect fetal neurobehavioral parameters, with the exception that fetuses of heavier smokers moved significantly less than those of lighter smokers at 36 weeks gestation. By the end of gestation, higher maternal buprenorphine dose was related to depression of baseline fetal cardiac measures at trough. CONCLUSION: Maternal buprenorphine administration has acute suppressive effects on fetal heart rate and movement, and the magnitude of these effects increases as gestation progresses. Higher dose (!13 mg) appears to exert greater depressive effects on measures of fetal heart rate and variability. These findings should be balanced against comparisons to gestational methadone effects, relatively good outcomes of buprenorphine-exposed infants, and recognition of the benefits of medication-assisted treatment for pregnant women with opioid use disorders in optimizing pregnancy outcomes. P roblems that result from consumption of licit and illicit opioids constitute a continually escalating national health crisis in the United States, 1, 2 as does the concurrent rise in opioid use disorders (OUDs). 3 Affected populations include pregnant women, which results in an increase in the prevalence of neonatal abstinence syndrome (NAS). 4 Because of the dual risk to mother and fetus, treatment (particularly opioid agonist treatment; OAT) is an increasing priority for this group. Until recently, the standard of care has been maternal treatment with methadone, a full mu-receptor agonist. However, buprenorphine, which is a partial agonist/ antagonist, has become an increasingly popular 5 World Health Organization 6 and American Society of Addiction Medicine 7 recommended medication choice since the publication of the findings from the Maternal Opioid Treatment: Human Experimental Research study, which reported amelioration of NAS severity in buprenorphine-exposed infants, compared with methadone. 8 Assessment of the fetus provides a way to evaluate the in situ and gestational effects of substances on the developing nervous system. 9 Two published reports compare buprenorphine with methadone exposure on aspects of fetal neurobehavior. In a pilot study, buprenorphine-exposed fetuses (n¼6) displayed indicators of greater fetal well-being at peak levels, which were assessed by measures of fetal heart rate (FHR) and motor activity in early and late gestation, respectively, compared with methadone-exposed fetuses. 10 In the other, buprenorphine treatment (n¼33) generated fewer changes in FHR parameters from trough to peak levels, compared with methadone treatment, that were evaluated at a single gestational period.
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The primary aim of this prospective, longitudinal study is to document more comprehensively the neurobehavioral development of the buprenorphineexposed fetus over time through measurement of fetal cardiac patterning and fetal motor activity and their integration. The acute effects of medication on fetal functioning were determined by comparison of fetal neurobehavioral parameters at times of maternal medication trough and peak during the second one-half of gestation and examination of the potential effect of buprenorphine dose. Given that the study relies on a clinical sample of women with substance use disorders, secondary 
Materials and Methods Participants
Eligibility was restricted to pregnant women with OUD and singleton generally uncomplicated pregnancies. Significant maternal conditions that independently could affect fetal functioning that included HIV infection, hypertension, and diabetes mellitus were exclusionary. Because of the nature of the population, use of other licit (eg, cigarettes) and illicit (eg, heroin) substances was not exclusionary, with the exception of current alcohol dependence to avoid potential teratogenic effects and/or heavy benzodiazepine use when the potential for withdrawal during the inpatient buprenorphine induction period was considered unsafe. A total of 127 women consented to participate. As seen in Figure 1 , 78 women left the protocol for a variety of reasons. Of those, 39 women (50%) remained in treatment but either switched to methadone or chose not to receive OAT, and 39 women (50%) left the treatment program altogether. The final sample was comprised of 49 women who attended a substance use disorder treatment facility. 12 Approval was granted by the governing institutional review board, and signed consent was obtained from all participants.
Procedures
At program intake, women who required OAT were offered participation in an open label clinical trial that provided buprenorphine as an alternative to methadone for the treatment of OUD. Participants included both clinically referred women who became pregnant while stable on buprenorphine (n¼11) and those who underwent a 3-day induction on our inpatient clinical research unit. The induction protocol included a period of opioid washout and attendant withdrawal because of buprenorphine's pharmacologic characteristics. Stable women whose condition was methadone-maintained were not offered study participation. Because participants were pregnant, no more than mild withdrawal based on frequent scoring with the use of the Clinical Opioid Withdrawal Scale 13 was tolerated before initial buprenorphine dosing. A maximal dose of 24 mg could be achieved by the third day of the induction protocol, after which participants returned to the treatment program as outpatients. Participants who entered the study as stable patients whose condition was buprenorphine-maintained were dosed with their maintenance dose and entered the treatment program as outpatients.
Participants received a single daily observed (through tablet dissolving) sublingual dose of mono-buprenorphine at approximately the same time each morning, with take-home dosing only when necessary and approved. All women received obstetric care at the treatment program from intake through delivery. Participants provided weekly urine specimens that were dipstick-screened for 10 substances; cut-off values are included in Table. Maternal-fetal monitoring procedure Data were collected during two 60-minute fetal monitoring sessions on 1 day during 24, 28, 32, and 36 weeks gestation based on dating ultrasound scanning. The sessions were timed at pharmacologic trough (just before (7), taste (4), conƟnued cravings (3), does not like the way it makes her feel (2) and reasons unclear (2) 10 meet study exclusion criteria: 8 prior to medicaƟon inducƟon for: IUGR (2), previously unknown high risk for preterm birth (2), mulƟple pregnancy complicaƟons (1), cholestasis of pregnancy (1)* oligohydramnios and PROM (1), acetaminophen overdose (1) 2 aŌer medicaƟon inducƟon for: cholestasis of pregnancy (1) and more than 3 episodes of alcohol use (1) 5 are administraƟvely discharged from drug treatment for: noncompliance with treatment requirements (3, including drug diversion in 1 of these), insurance reasons (2) 16 leave the inpaƟent research unit during inpaƟent inducƟon: for reasons unknown (8) , nausea and vomiƟng (3), child care emergencies (2), other family emergency (1), court date (1), "boredom" (1) 2 are non-compliant with study procedures 2 are hospitalized for psychiatric concerns 8 for assorted reasons: Transfers to a long term residenƟal program (1) Opts for methadone before inducƟon (1) Does not withdraw on CRU and is not medicated (1) Found not to be on a stable dose of buprenorphine, despite claims to the contrary (1) Leaves treatment aŌer inducƟon to care for a sick child, is too late in pregnancy to be readmiƩed to the study when she returns to treatment (1) Lives too far from the treatment program (1) Transfers to another OB provider (1) and another treatment program (1) *1 woman with presumed cholestasis of pregnancy was delivered at near term and remained in the protocol Enrollment flowchart for study participants. Original Research OBSTETRICS ajog.org the daily dose) and peak (2.5 hours after the dose) maternal buprenorphine levels.
Fetal data were recorded with a fetal actocardiograph (Toitu MT325; Toitu, Tokyo, Japan) with the use of a transabdominal Doppler transducer. Fetal data were collected from the output port of the monitor and digitized at 1000 Hz through an internal A/D board with the use of streaming software. Off-line processing of fetal data was accomplished through customized software (GESTATE; James Long Company, Caroga Lake, NY).
Quantification of fetal neurobehavioral measures
FHR FHR underwent error rejection procedures that were based on moving averages of acceptable values as needed. FHR variability (FHRV) was computed continuously (ie, root mean square of each 1-minute epoch of FHR averaged over the recording period) and episodically (ie, count of accelerations defined as excursions in FHR !10 beats/ min for !15 seconds).
Fetal movement (FM)
The actograph reliably detects fetal motor activity by preserving the remaining signal after band-passing frequency components of the Doppler signal that are associated with FHR and maternal somatic activity.
14 Movement bouts were identified each time the signal attained amplitude of 15 units until there was a cessation of signal for at least 10 seconds. Motor activity reflects the number of bouts multiplied by their mean duration and yields a measure of the amount of time that the fetus spent moving, in seconds. The integration between FMs and FHR (FM-FHR coupling) was quantified as the proportion of time that individual movements were associated with a change in FHR, using previously developed criteria. 15 FM-FHR coupling reflects coactivation of the sympathetic and parasympathetic components of the autonomic nervous system.
Data analysis
Not all participants were available for the fetal assessment at each gestational age. For the 49 participants, visits were distributed in the following manner: 20 participants (24 weeks gestation), 30 participants (28 weeks gestation), 42 participants (32 weeks gestation), and 40 participants (36 weeks gestation). Most women participated on !2 occasions (n¼41; 83.6%). Distributions for each fetal variable were examined for outliers. To examine the change in fetal neurobehavior from trough to peak and within and across gestational periods, data analysis relied on hierarchic linear modeling via the mixed procedure in SAS software (version 9.4; SAS Institute Inc, Cary, NC), which accounts for dependency in data measured repeatedly on the same individuals. An advantage of the hierarchic linear modeling approach is that it uses all available data by using Participants with !1 positive screening, n (%) 29 (59) a Substance screened for included opiates (n¼12; 41%), tetrahydrocannabinol (n¼10; 34%), benzodiazepines (n¼11; 38%), cocaine (n¼8; 28%), opioid-containing pain relievers (n¼6; 21%), methadone (n¼4; 14%), methamphetamine (n¼2; 7%), amphetamines (n¼1; 3%), barbiturates (n¼0), and buprenorphine (n¼49; 100%). Cut-off values for urine toxicology screenings included opiates (morphine; 300 ng/mL), tetrahydrocannabinol (50 ng/mL), benzodiazepines (300 ng/mL), cocaine (300 ng/mL), opioid-containing pain relievers (100 ng/mL), methadone (300 ng/mL), methamphetamine (500 ng/mL), amphetamines (1000 ng/mL), barbiturates (300 ng/mL), and buprenorphine (10 ng/mL). ajog.org
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restricted maximum likelihood estimation within the model framework, eliminating list-wise deletion. Five models (1 for each fetal measure) were constructed with buprenorphine level at peak or trough, gestational age (4 points), and an interaction term (level X gestational age) as predictors. Dose effects were examined with a similar approach for fetal neurobehaviors measured at peak and trough. Mean buprenorphine dose was dichotomized via median split and entered as a categoric predictor of change in fetal parameters from trough to peak; dose effects were estimated separately at each gestational age. Given the small sample size, polysubstance exposures (other drugs and cigarette smoking) were not evaluated as covariates or modifying variables; rather, dichotomous variables and change scores from peak to trough were created, and group differences were evaluated by t-tests.
Results
On average, participants were 27.6 years old (standard deviation, 4.4) with 11.5 years of education (standard deviation, 1.9), and primarily white (43; 87.8%); 6 participants (12.2%) were African American. Most participants were multigravid (41; 83.7%). As expected with a clinical sample of women with OUD, there was evidence of illicit drug use and licit drug misuse during treatment; the Fetal heart rate (bpm)
GestaƟonal age (wks) trough peak Buprenorphine administration was associated with significantly slower fetal heart rate at 28, 32, and 36 weeks gestation; no difference was observed at 24 weeks gestation.
bpm, beats per minute.
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FIGURE 3
Fetal heart rate variability Buprenorphine administration was associated with significantly reduced fetal heart rate variability at 32 and 36 weeks gestation; no difference was observed at earlier gestational ages. P<.0001). Buprenorphine did not affect overall fetal motor activity ( Figure 5) , with the exception of a suppressive effect at 36 weeks gestation (b¼408.71; SE¼144.20; P¼.008). Similarly, the effect on FM-FHR coupling ( Figure 6 ) was limited to the final assessment period (b¼.05; SE¼0.02; P¼.002), and reflects a reduction in this parameter after buprenorphine administration.
Contribution of dose
There was variation in the daily buprenorphine treatment dosage that ranged from a single 2-mg tablet to 28 mg (Table) . Within individuals, buprenorphine dose was highly stable over time (M correlation coefficient between visits, r¼0.94). Moreover, it was uncommon for dosing to change during treatment; dose for only 3 participants (6%) varied by >4 mg. As a result, a dichotomous variable was created that was based on median dose (<13 mg [n¼24] vs !13 mg [n¼25]) to examine associations with fetal measures at trough and peak and the degree of change from trough to peak. Fetuses who were exposed to chronically higher buprenorphine doses showed reduced FHR at trough across gestational ages (F (1, 49)¼10.30; P¼.002). Higher dose was also associated with reduced FHRV and fewer accelerations at trough at 32 and 36 weeks gestation (P¼.038 and .017, respectively). Figure 7 provides a visual representation of 36-week results. FM-FHR coupling was also depressed at trough in the higher dosage group, but only at 32 weeks gestation (P ¼.006); motor activity was unaffected.
Dose associations with fetal measures were largely absent at peak. However, and somewhat paradoxically, by 36 weeks gestation and at times earlier in gestation, computation of change scores of fetal parameters from trough to peak revealed that fetuses who were exposed to lower treatment doses reacted with greater suppression in FHR (P¼.020) and reduction in accelerations (P¼.014) in response to buprenorphine administration, which was most likely the result of a floor effect of already diminished cardiac variability in the higher dose group.
Polysubstance exposure
On average, participants had 16 toxicology screenings during the protocol FIGURE 4 Fetal heart rate accelerations Buprenorphine administration was associated with significantly fewer fetal heart rate accelerations at 32 and 36 weeks gestation; no difference was observed at earlier gestational ages. (Table) . Twenty participants (41%) had no positive findings through delivery; of the remaining 59%, evidence of use was detected one-third of the time; detected substances are presented in the Table. Because of limitations in sample size, the potential confounding influence of specific substances could not be evaluated; instead, comparisons were made between fetuses of participants who were abstinent (18;45%) vs not abstinent (22;55%) through 36 weeks gestation. None of the fetal neurobehavioral parameters at either trough or peak nor change scores from trough to peak were significantly different in abstinent vs not abstinent groups (P range from 0.10e0.98). Buprenorphine treatment dose was unrelated to abstinence (c 2 ¼1.61; P¼.204). Because nearly all participants smoked and there was high stability over time in the number of cigarettes smoked per day over gestation (r range from 0.75e0.92), mean values were computed and dichotomized as <9 (n¼20) vs !10 (n¼29) cigarettes smoked per day. At 36 weeks gestation, smoking dosage was not significantly associated with fetal behaviors at trough or change from trough to peak with 1 exception: fetuses of heavier smokers moved significantly less than those of lighter smokers (M¼1980.9 and 1051.8, respectively; t (38)¼3.33; P¼.002. Acute buprenorphine exposure generated less reduction in fetal motor activity in the heavier smokers (t (38)¼3.11; P¼.004), which is likely a result of the chronic reduction in motor activity that was evident at trough in this group.
Comment
Participant attrition in research that involved substance-using populations is common, as was the case in this study. However, although attrition was high, dissatisfaction with buprenorphine per se was only a stated factor in 21 cases (27%). Complaints of nausea and vomiting, which are common pregnancy symptoms, accounted for another 10 cases (13%). Anecdotally, some women who left the protocol to switch medications had a better clinical response to methadone, which emphasizes the importance of medication choice for women with OUDs and the value of research in this arena. Three women on higher doses experienced cholestasis of pregnancy. All 3 women had concurrent hepatitis C virus infection, and there is evidence to suggest that the risk of the development of cholestasis of pregnancy is increased in women who are infected with hepatitis C virus. [16] [17] [18] [19] We could find no reports of increased risk for this condition that was associated with buprenorphine administration; however, a potential association with dose should be evaluated in future studies.
With respect to the main study objectives, we consistently found that, when comparing fetal neurobehavioral expression between pharmacologic trough and peak, buprenorphine exposure depressed FHR and both measures of variability in heart rate. Effects increased in magnitude as gestation progressed, particularly at !28 weeks gestation. Fetal motor activity and FM-FHR coupling were also depressed, but only at 36 weeks gestation. In general, this pattern reveals that fetal neurobehavioral parameters are most affected as they mature. From a methodologic perspective, the lack of acute effects at <28 weeks gestation highlights the value of assessment of the fetus at multiple points in gestation; the collection of data at only 24 weeks gestation, for example, would have generated inaccurate conclusions about buprenorphine's effects.
The current findings are consistent with 2 earlier reports of maternal buprenorphine and fetal neurobehavior that found some suppression of fetal functioning (FHR, heart rate variability, accelerations) 10, 11 and movement 10 with maternal buprenorphine maintenance. The degree to which buprenorphine confers greater or lesser effects than methadone on the developing fetus cannot be addressed by this study because there was no direct comparison to a methadone-exposed group. However, comparison with findings from an earlier study that the same methods and design applied to a methadonemaintained population (n¼40) 20 tentatively suggested that buprenorphine affects fetal functioning less than methadone. For example, at 36 weeks gestation methadone-exposed fetuses showed a 37% reduction in FHR variability and 46% decrease in motor activity at peak compared with the 27% reduction in FHR variability and 28% reduction in Fetal movement-fetal heart rate coupling Buprenorphine administration was associated with significantly less fetal movementefetal heart rate coupling at 36 weeks gestation, but not earlier. Developmental trends in fetal neurobehaviors are apparent in Figures 2e6 and are somewhat attenuated compared with noneopioid-dependent populations. 9, 21 However, trough levels were associated with maternal dose, such that higher doses were significantly associated with slower FHR and reduced variability, despite medication levels being at nadir. This relation was present at !32 weeks gestation and suggests a lingering and perhaps cumulative medication effect at higher doses (ie, !13 mg). This finding resonates with a recent report that used the same sample that found that maternal buprenorphine dose and concentrations of buprenorphine in plasma of recently delivered women are correlated, 22 which is a relationship that was not found with methadone.
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The unexpected dose-effect generated a paradoxic finding of less suppression of fetal reactivity to higher doses of buprenorphine. For example, the mean change in accelerations at 36 weeks gestation from trough to peak was 4.6 per 60 minutes in the lower dose group, but only 1.4 in the higher dose. However, the lower dose exhibited twice as many accelerations at trough (7.0e3.5), which suggests that fetal functioning in the higher dose group was already at somewhat of a floor.
In contrast to other studies that impart strict controls on non-OAT other substance use to better isolate treatment medication effects, the current study reflects the real world situations that are encountered in standard drug treatment centers, which includes participant relapse and multiple licit and illicit exposures. Thus, evaluation of buprenorphine effects in this group more closely approximates typical implementation. We did not find continued misuse of other substances in addition to buprenorphine treatment to be associated with alterations in fetal neurobehaviors at trough. Lack of abstinence also did not exert a differential effect on the acute response to buprenorphine, with the exception of nicotine. Heavier smoking was associated with suppression of fetal motor activity, which confirmed previous observations. 24, 25 Caution is needed in concluding that other substances do not potentiate or interfere with the fetal response to buprenorphine, because the small sample coupled with variation in exposures limits our ability to conduct more detailed analyses and use other substances as either covariates or modifiers. In particular, this study may be underpowered to detect significant effects of other substances on either fetal parameters or in relation to buprenorphine effects.
OAT for pregnant women with OUDs is often necessary enable them to seek prenatal care, prepare for childbirth, address trauma, find employment, and reduce other substance use/misuse. In many women who are able to tolerate it, buprenorphine may be a better option than methadone, based on findings of Number of fetal heart rate acceleraƟons
At buprenorphine trough, 36-week fetuses of women who were treated with higher buprenorphine dose (!13 mg) presented with slower fetal heart rate, lower fetal heart rate variability, and approximately one-half the number of fetal heart rate accelerations as compared with fetuses of women who were treated with a lower dose. 
